Remdesivir props up Gilead’s declining fortunes – Boston, Massachusetts

Boston, Massachusetts 2021-07-30 09:12:56 –

NSEverything in the morning. Damian Gard here replaces Ed Silberman during the declining hours of another summer working week. At least in this part of the world, the gray sky turns into sunshine, and weekends promise good enough weather to give the beach a chance, even for our most sea-hating people. .. But until then, there are deadlines, emails, and intolerable video conferencing. Here are some choices of interest to help you get over it.

Sale of Gilead Sciences (GILD) Remdesivir exceeded analysts’ expectations in the second quarter, for a total of $ 829 million., Reuters note.. The amazing performance of this drug helped overcome the decline of Gilead’s core business of selling HIV treatments, but the uncertain long-term demand for remdesivir given to patients admitted with Covid-19 It makes it difficult to predict how much benefit a drug will bring.

Sign up for STAT + to unlock this article and enjoy the first 30 days for free!

let’s start

Remdesivir props up Gilead’s declining fortunes Source link Remdesivir props up Gilead’s declining fortunes

Back to top button